Tag:
generic blocking
Latest Headlines
Latest Headlines
Supreme Court could upend pay-for-delay deals
Now that Obamacare has had its day at the Supreme Court, pharma has another case to worry about. The longstanding debate over "pay-for-delay" deals with generics companies could soon make its way to the high court, legal experts say. And if it does, branded drugmakers and generics companies would face a wholesale shift in their business strategies.
Appeals court ruling threatens pay-to-delay deals
A federal appeals court pulled a pay-to-delay challenge out of mothballs, forcing Merck to fight claims that its Schering-Plough unit delayed generic versions of its potassium drug K-Dur. But Merck isn't the only drugmaker that should keep an eye on this case.
Judge denies AZ's bid to stop Seroquel copies, but chides FDA
AstraZeneca took another shot at stopping generic Seroquel--and lost, at least so far.
U.K. accuses Servier of generic-blocking, sues for £220M
The pay-for-delay battle is now in U.K. court. Health Secretary Andrew Lansley has sued the French drugmaker Servier for £220 million ($361.3 million), claiming that the company blocked generic
EU antitrust campaign begins with Servier probe
After an 18-month probe, E.U. antitrust regulators say they're embarking on a campaign for sweeping change in the pharma business. Generics take too long to get to market, they say, an average of
U.S., EU getting tough on "pay-for-delay"
Forces are aligning against "pay-for-delay" patent settlements. After years of pooh-poohing the Federal Trade Commission's fight against the deals, the U.S. Justice Department now has signed up for
FTC: Kill pay-for-delay, save $35B
Would you like to save $35 billion on healthcare? Trick question, right? Put the words "save" and "billion" and "healthcare" in the same sentence these days, and you'll probably get a call from
Supremes won't review pay-for-delay case
The U.S. Supreme Court passed on a chance to check out "pay for delay" deals between drugmakers and generics firms. Bad news for critics of those deals, which happen to include the federal
Ex-BMS exec sentenced to write Plavix book
U.S. District Judge Ricardo Urbina apparently believes the old adage that everyone has at least one book in them. Judge Urbina sentenced a former Bristol-Myers Squibb exec to write one--in penance
Battle over generic-delaying continues
Yesterday, the congressional Subcommittee on Commerce, Trade, and Consumer Protection held a meeting to discuss Congressman Bobby Rush's (D-IL) new H.R.1706 bill--otherwise known as Protecting
